首页 | 本学科首页   官方微博 | 高级检索  
检索        

miR-222通过下调DDIT4抑制肾癌细胞自噬
引用本文:倪晓辰,赵志红,马永良,等.miR-222通过下调DDIT4抑制肾癌细胞自噬[J].中国癌症杂志,2015,25(3):161-166.
作者姓名:倪晓辰  赵志红  马永良  
作者单位:河北医科大学第四医院泌尿外科,河北 石家庄 050011
基金项目:河北省医学科学研究重点课题计划(20110142)。
摘    要: 背景与目的:微小RNA(microRNA,miRNA,miR)在肿瘤的发生、发展中具有重要的作用。miR-222在多种肿瘤组织中表达上调,而其在肾癌(renal cell carcinoma,RCC)中的表达及其作用机制尚不清楚。本研究拟通过检测RCC组织及相应癌旁组织中miR-222的表达情况,探讨miR-222在RCC中的作用。并在体外条件下,通过检测miR-222的下游作用靶点,探讨miR-222的抗RCC作用机制。方法:采用实时定量聚合酶链反应(quantitative real-time polymerase chain reaction,qRT-PCR)检测RCC组织和癌旁组织中miR-222的表达;采用CCK-8法检测细胞的增殖活力;采用蛋白质]印迹法(Western blot)检测DDIT4蛋白及LC3-Ⅱ的表达;采用荧光素酶实验验证miR-222的作用靶点;转染EGFP-LC3后在激光共聚焦显微镜下观察细胞自噬状态。结果:qRTPCR检测结果显示,miR-222在RCC组织中表达明显上调。在人肾透明细胞癌786-O细胞株中敲低miR-222表达后显著抑制细胞的增殖活力,而过表达miR-222可增强786-O细胞的增殖活力(P<0.01)。在786-O细胞中敲低miR-222后,其靶基因DDIT4蛋白的表达显著上调,过表达miR-222后,DDIT4表达明显下调。荧光素酶实验结果表明,DDIT4为miR-222的直接作用靶点。RCC组织的DDIT4表达下调。在786-O细胞中抑制miR-222表达后,LC3-Ⅱ的表达水平显著上调,自噬体数目显著增加。结论:miR-222在RCC中高表达,并可能通过靶向抑制DDIT4的表达参与调控RCC细胞自噬。

关 键 词:miR-222  肾癌  DDIT4  自噬  

miR-222 can inhibit the autophagy of renal cell carcinoma cells through down-regulating the expression of DDIT4
NI Xiaochen,ZHAO Zhihong,MA Yongliang,et al.miR-222 can inhibit the autophagy of renal cell carcinoma cells through down-regulating the expression of DDIT4[J].China Oncology,2015,25(3):161-166.
Authors:NI Xiaochen  ZHAO Zhihong  MA Yongliang  
Institution:Department of Urology, the Fourth Hospital of Hebei Medical University, Shijiazhuang Hebei 050011, China
Abstract:Background and purpose: MicroRNA (miRNA, miR) plays an important regulatory role in cancer. miR-222 is reported to be up-regulated in various tumors, but its role in renal cell carcinoma (RCC) remains unclear. In this study, we detected the expression of miR-222 in both RCC and adjacent tissue samples. The aim of this study was to investigate the role of miR-222 in RCC. Methods: The expression levels of miR-222 in RCC tissue samples were quantified by quantitative real-time polymerase chain reaction (qRT-PCR). DDIT4 and LC3-Ⅱ protein expressions were determined by Western blot. Dual luciferase assay was performed to verify the target of miR-222. EGFP-LC3 microscopy assay was performed to assess autophagy. Results: Results from qRT-PCR showed that the expression of miR-222 was up-regulated in RCC tissues. Knockdown of miR-222 with specific antagomiR decreased the cell viability of 786-O cells, whereas overexpression of miR-222 increased the cell viability (P<0.01). The levels of DDIT4 were upregulated in 786-O cells transfected with miR-222 antagomiR, whereas overexpression of miR-222 induced the downregulation of DDIT4 expression. Data from dual luciferase assay indicated that miR-222 directly targeted the expression of DDIT4. Consistently, the expression of DDIT4 in RCC tissues was down-regulated compared with adjacent tissues. Knockdown of miR-222 in 786-O cells induced a significant increase of autophagosome formation and LC3 lipidation.These results supported that miR-222 could inhibit autophagy in RCC cells, which may affect the clinical characteristcs of RCC. Conclusion: miR-222 is up-regulated in RCC and can inhibit the autophagy of RCC cells through downregulating the expression of DDIT4.
Keywords:miR-222  Renal cell carcinoma  DDIT4  Autophagy  
点击此处可从《中国癌症杂志》浏览原始摘要信息
点击此处可从《中国癌症杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号